Onconetix Inc
ONCO
Company Profile
Business description
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
Contact
201 East Fifth Street
Suite 1900
CincinnatiOH45202
USAT: +1 513 620-4101
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
5
Stocks News & Analysis
stocks
After slump this ASX share may be an opportunity
Lower than expected guidance led to a sell-off.
stocks
Investment decisions in overvalued bank drive strong results
Shares fall despite a broadly unchanged outlook.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,122.80 | 29.40 | -0.32% |
| CAC 40 | 8,055.51 | 105.33 | 1.32% |
| DAX 40 | 23,959.99 | 390.03 | 1.65% |
| Dow JONES (US) | 47,368.63 | 381.53 | 0.81% |
| FTSE 100 | 9,787.15 | 104.58 | 1.08% |
| HKSE | 26,649.06 | 407.23 | 1.55% |
| NASDAQ | 23,527.17 | 522.64 | 2.27% |
| Nikkei 225 | 50,911.76 | 635.39 | 1.26% |
| NZX 50 Index | 13,607.61 | 9.87 | -0.07% |
| S&P 500 | 6,832.43 | 103.63 | 1.54% |
| S&P/ASX 200 | 8,846.70 | 28.90 | -0.33% |
| SSE Composite Index | 4,018.60 | 21.04 | 0.53% |